Effects of chronic oral administration of a new beta-blocker, bopindolol, on serum lipoprotein concentrations and blood pressure of spontaneously hypertensive rats. 1989

T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
Department of Pharmacology, Niigata University School of Medicine, Japan.

The effects of chronic oral administration of bopindolol (twice daily for 12 weeks beginning at 5 weeks of age) on serum lipoprotein concentrations, blood pressure and heart rate, were studied in spontaneously hypertensive rats. They were compared with those of two other beta-blockers. Bopindolol and propranolol (15 mg/kg) attenuated the increase in heart rate. Pindolol produced a similar, gradual change in heart rate, but only after the 6th week of treatment. Propranolol and bopindolol attenuated the development of hypertension, whereas pindolol showed no such effect. Pindolol and bopindolol produced a significant increase in high-density lipoprotein cholesterol concentration, but did not produce an increase in serum creatine phosphokinase activity. Administration of these drugs in an acute regimen at 10 weeks of age, provoked changes in blood pressure and heart rate, reflecting partial agonist activities of varying degree, in agreement with the results obtained in chronic experiments with regard to serum lipoprotein concentrations. Pindolol (5 mg/kg) provoked a larger decrease of blood pressure without decrease of heart rate, while the decrease of blood pressure after bopindolol (5 and 15 mg/kg) was associated with a decrease of heart rate. It was concluded that bopindolol is a beta-adrenergic blocking agent with a mild partial agonist activity and devoid of adverse effects on lipid metabolism.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D010869 Pindolol A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) Prindolol,LB-46,Visken,LB 46,LB46
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine

Related Publications

T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
November 2003, American journal of hypertension,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
March 1988, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
September 1983, Biochemical pharmacology,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
January 1983, Clinical and experimental hypertension. Part A, Theory and practice,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
February 2002, Pharmacology,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
December 1981, Clinical science (London, England : 1979),
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
January 1989, Archives internationales de pharmacodynamie et de therapie,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
January 1988, Drugs,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
June 1994, American journal of hypertension,
T Ishihara, and W P Chin, and Y Yoshida, and H T Sun, and A Mitomi, and T Ishibashi, and K Tamura, and S Imai
January 1987, Nephron,
Copied contents to your clipboard!